Current setbacks cannot prevent gene-editing companies from advancing closer to “one-and-done” cures and new products.

Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.

About 150 people in Singapore have transthyretin amyloid cardiomyopathy. Read more at straitstimes.com. Read more at ...

The recent announcement of the resurrection of the dire wolf generated considerable global media attention and widespread ...

The mood at the annual meeting of the American Society of Cell and Gene Therapy isn’t amazing. The biotech market has been ...

In a new study published in Cell Reports, researchers at the University of Freiburg reveal how a disordered protein segment ...

Crispr-Cas9 is a tool for making precise edits in DNA, discovered in bacteria. The acronym stands for 'Clustered Regularly ...

Leading trade organizations representing the makers of cell and gene therapies are calling for a 10-year moratorium on ...

Danforth Technology Company launched Spearhead Bio to make the process of gene editing faster and more efficient.

India develops climate-resilient, high-yielding rice varieties using genome editing technology, sparking debate on GM crops.

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...